All posts by: Michael Zand

Mesoblast Partners With Cartherics to Develop ‘off-the-shelf’ Cell-based Immunotherapies for Solid CancersRelapsed …
Markets Insider
NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR–T cells …

Mesoblast Partners With Cartherics to Develop ‘off-the-shelf’ Cell-based Immunotherapies for Solid Cancers
GlobeNewswire (press release)
NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR–T cells …

and more »

In Utero Stem Cell Transplants Could Revolutionize Thalassemia Treatment
Technology Networks
Newborn Elianna is held by her mother, Nichelle Obar, and father, Chris Constantino. Elianna was born at UCSF Benioff Children’s Hospital San Francisco after receiving an in utero stem cell transplant to treat a lethal form of thalassemia. Credit: Noah …
UCSF performs first-ever transplant in a fetusThe Mercury News

all 3 news articles »

In Utero Stem Cell Transplants Could Revolutionize Thalassemia Treatment
Technology Networks
Newborn Elianna is held by her mother, Nichelle Obar, and father, Chris Constantino. Elianna was born at UCSF Benioff Children’s Hospital San Francisco after receiving an in utero stem cell transplant to treat a lethal form of thalassemia. Credit: Noah …

In Utero Stem Cell Transplants Could Revolutionize Thalassemia Treatment
Technology Networks
Newborn Elianna is held by her mother, Nichelle Obar, and father, Chris Constantino. Elianna was born at UCSF Benioff Children’s Hospital San Francisco after receiving an in utero stem cell transplant to treat a lethal form of thalassemia. Credit: Noah …

Spark’s Gene Therapy For Hemophilia B Looks To Change Up The Game
Seeking Alpha
Spark Therapeutics posts positive phase 1/2 results treating patients with Hemophilia B using SPK-9001. Pfizer is expected to lead the rest of the development for the Hemophilia B candidate SPK-9001 by this summer since it is partnered with Spark.

World Gene Therapy Research Report 2018: Profiles of 183 Companies Presented Along with 250 Collaborations
GlobeNewswire (press release)
Dublin, May 29, 2018 (GLOBE NEWSWIRE) — The “Gene Therapy – Technologies, Markets and Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering. Gene therapy technologies are described in detail including …
Global Gene Therapy Market Pin-Point Analysis to 2026: Amgen , Spark Therapeutics , Oxford BioMedica PLC …satPRnews (press release)
Hemophilia Gene Therapy Market Plying for Significant Growth During 2025The Columnist

all 3 news articles »